Skip to main content

Table 2 Ranibizumab Treatment and Outcomes Before Switch to Intravitreal Aflibercept

From: Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration

(n = 125)
Delay between diagnosis of nAMD and first injection of ranibizumab, months 0.5 (1.2)
Number of ranibizumab injections 4.8 (1.9)
Duration of ranibizumab treatment, months 4.9 (2.8)
BCVA before any treatment (including ranibizumab), ETDRS letters 64.0 (15.6)
BCVA at baseline (switch to IVT-AFL), ETDRS letters 66.2 (12.1)
 Change in BCVA from before the start of any treatment (including ranibizumab) and baseline (switch to IVT-AFL) 2.2 (12.0)
 P value 0.046
  1. All values are expressed as mean (standard deviation); per-protocol population
  2. P value is for paired sample t test
  3. BCVA Best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, IVT-AFL Intravitreal aflibercept, nAMD Neovascular age-related macular degeneration